ライフサイエンスコーパス: adjuvant

1 ients were included (531 neoadjuvant and 534 adjuvant).

2 SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.

3 mmunity to subunit vaccines using a clinical adjuvant.

4 mbination with TLR4 ligand-emulsion (GLA-SE) adjuvant.

5 anted by a co-administered cell reactive CpG adjuvant.

6 sing a protein subunit vaccine with a potent adjuvant.

7 s single- or 2-dose regimens with or without adjuvant.

8 on anti-CD40 DNA aptamers as a novel vaccine adjuvant.

9 ared to SCIT with alum, without the need for adjuvant.

10 istered subcutaneously without an additional adjuvant.

11 d aspirin-triggered-resolvin D1 (AT-RvD1) as adjuvants.

12 essential component of nanoemulsion vaccine adjuvants.

13 tive targets for novel antibiotics and their adjuvants.

14 of virus-like particles, biologics or novel adjuvants.

15 CpG-1826 and Montanide ISA 720 were used as adjuvants.

16 mulation of recombinant antigens with potent adjuvants.

17 ns for the screening and evaluation of novel adjuvants.

18 ed therapeutically as antivirals and vaccine adjuvants.

19 0.5-mL subcutaneous injection of 500 ug of adjuvanted (1 dose) or nonadjuvanted (2 doses) FLU-v (A-

20 It is most notably in the MF59 adjuvant, a component in some seasonal influenza vaccine

21 h bee venom PLA(2) and murine sPLA(2)-X have adjuvant activity, leading to a type 2 immune response i

22 a complete allergen that induces endogenous adjuvant activity.

23 izations, when formulated with the MF59-like adjuvant AddaVax, the RBD derivative elicited neutralizi

24 he neoadjuvant group, and the arms receiving adjuvant ADT were combined into the adjuvant group.

25 er augmented by combination with a human-use adjuvant ALFQ that contains immune-stimulators.

26 ntrol rats (n = 6) were injected with Freund adjuvant alone.

27 ts were assigned to receive the vaccine with adjuvant and 25 without adjuvant, and 23 participants we

28 active anticancer treatment in a neoadjuvant/adjuvant and 560 of 1,016 (55.1%) in a palliative settin

29 The TLR5 agonist flagellin is a potent adjuvant and is currently being developed for use in vac

30 ies, and the use of CDK4/6 inhibitors in the adjuvant and neoadjuvant settings, thereby further expan

31 prior research, we found that the egg-based adjuvanted and HD vaccines were slightly more effective

32 d be independently tuned to allow release of adjuvants and antigen from days up to two weeks.

33 nostimulatory oligonucleotides (CpG-1826) as adjuvants and encapsulate lysates derived from TNBC cell

34 latory activity of a panel of TLR triagonist adjuvants and found that they elicited unique Ag-specifi

35 rime-boost vaccine regimens, and potentially adjuvants and immunogen dose, influence the elicitation

36 recognition receptor agonists are effective adjuvants and immunotherapeutic agents.

37 ive the vaccine with adjuvant and 25 without adjuvant, and 23 participants were assigned to receive p

38 e majority of participants, more common with adjuvant, and of short duration (mean, <=2 days).

39 materials are ideal for antigen delivery, as adjuvants, and as mimics of viral structures.

40 t, hence PI3Kbeta inhibition may be a useful adjuvant antiangiogenesis therapy with sunitinib.

41 Adjuvants are central to the efficacy of subunit vaccine

42 Four adjuvants are used in products marketed in Europe: alumi

43 metastatic breast cancers (MBC) resistant to adjuvant aromatase inhibitor (AI) therapy.

44 which are equally as efficacious as vaccine adjuvants based on physiochemical properties and immunom

45 Outcomes of patients with relapse after adjuvant BEP seem better compared with patients who expe

46 with CSI NS who experienced a relapse after adjuvant bleomycin, etoposide, and cisplatin (BEP) from

47 and DNA plasmid plus gp120 protein plus MF59 adjuvant boost.

48 ds considerable expense and some toxicity to adjuvant breast cancer chemotherapy.

49 First, we show that EP acts as an adjuvant by enhancing local inflammation, notably via gr

50 These fragments are then adjuvanted by a co-administered cell reactive CpG adjuva

51 designed to co-deliver protein antigens and adjuvants can promote their delivery to antigen-presenti

52 Among these new adjuvant candidates, VSA-2 (5b), a derivative of Momordi

53 e prepared a number of saponin-based vaccine adjuvant candidates.

54 Currently, there are no approved adjuvants capable of driving a Th17 response in a vaccin

55 onists may comprise a novel class of vaccine adjuvants capable of inducing cellular immune responses

56 03-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemo

57 ked foods of any ingredient or technological adjuvant causing allergies is required by EU food legisl

58 The experimental arm received adjuvant cetuximab.

59 e first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy.

60 ery is the preferred mode of treatment, with adjuvant chemoradiotherapy used for malignant thyroid me

61 The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in

62 patients treated with upfront resection and adjuvant chemotherapy (DM 83.0%, LR 16.9%) regardless of

63 neural invasion (HR = 1.50 [1.01-2.23]), and adjuvant chemotherapy (HR = 0.69 [0.48-0.97]) were indep

64 d June 2013, 180 HNSCC patients eligible for adjuvant chemotherapy after surgery with curative intent

65 Among these patients, 179 (35.5%) had adjuvant chemotherapy and 325 (64.5%) had no adjuvant tr

66 cognitive impairment (CRCI) is common during adjuvant chemotherapy and may persist.

67 ) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus rad

68 The role of routine adjuvant chemotherapy and radiotherapy is not clearly es

69 The addition of radiation to adjuvant chemotherapy did not significantly improve over

70 atures (nodal or margin involvement or LVI), adjuvant chemotherapy followed by radiation provides a b

71 n-inferiority of 3 months versus 6 months of adjuvant chemotherapy for patients with stage III colon

72 rnational consensus exists on the benefit of adjuvant chemotherapy for patients with UTUCs after neph

73 abine-based chemoradiation and postoperative adjuvant chemotherapy impairs tolerability and feasibili

74 Perioperative or adjuvant chemotherapy improves survival in patients with

75 The need for adjuvant chemotherapy in stage II colon cancer is still

76 Determine whether adjuvant chemotherapy is associated with a survival bene

77 assurance to patients and clinicians in whom adjuvant chemotherapy is indicated to reduce recurrence

78 herapy followed by surgery and the remaining adjuvant chemotherapy or to immediate surgery, followed

79 ntario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer a

80 ts who underwent tumor resection and started adjuvant chemotherapy showed improved survival with preo

81 Adjuvant chemotherapy significantly improved disease-fre

82 ion, T-stage, N-stage, resection margin, and adjuvant chemotherapy were correlated with OS and DFS.

83 without adjuvant therapy and 90 who received adjuvant chemotherapy with or without radiation (22%).

84 both unadjusted and multivariable analysis, adjuvant chemotherapy with or without radiation was not

85 In this analysis, adjuvant chemotherapy with or without radiation was not

86 expression in combination may identify which adjuvant chemotherapy-treated TNBC patients have a highe

87 on the basis of MammaPrint may safely avoid adjuvant chemotherapy.

88 therapy or to immediate surgery, followed by adjuvant chemotherapy.

89 One treatment strategy after orchiectomy is adjuvant chemotherapy.

90 urgical cytoreduction and neoadjuvant versus adjuvant chemotherapy.

91 ccording to whether or not patients received adjuvant chemotherapy.

92 relapsed within 12 months of neoadjuvant or adjuvant chemotherapy.

93 ression regimen or secondary prevention with adjuvant chemotherapy.

94 tures (median survivals: 54.6 vs 42.7 mo for adjuvant chemotherapy; HR=0.90; 95% CI: 0.75-1.08; P = 0

95 particles per 0.5 mL) combined with 250 mug adjuvanted clade C gp140 protein.

96 BRAF-mutant melanoma in both therapeutic and adjuvant clinical settings.

97 gher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which persist

98 his study, we demonstrate that a combination adjuvant composed of cyclic-di-AMP (cdAMP) and the plant

99 ot exhibit delayed acquisition compared with adjuvant controls.

100 isk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologi

101 Adjuvant dabrafenib plus trametinib reduced the risk of

102 pa1) in glucan-chitin particles (GCPs) as an adjuvant-delivery system.

103 However, the question remains as to whether adjuvant-dependent modulation of T(fh) cells enhances HI

104 d only 6 treatments and one fifth of the PNA adjuvant dose, with improved outcomes when compared with

105 of CD4+ and CD8+ cells in tumours receiving adjuvant drug combination.

106 SG15 to LFA-1 in vitro were required for its adjuvant effect in vivo.

107 Different molecular chemokine/cytokine adjuvants effected significant alterations to the recrui

108 Further, the adjuvant effects of sPLA(2)-X that result in the type 2-

109 ovide new insights into the basic biology of adjuvant-elicited cellular immunity and have clear impli

110 ositive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen f

111 Adjuvant epigenetic therapy that uses low-dose DNA methy

112 Adjuvant EPx2 for PS II NSGCT is highly effective, has a

113 : NCT00958737) investigating the duration of adjuvant fluorouracil, leucovorin, and oxaliplatin or ca

114 bination of Nano-11 and cdAMP is a promising adjuvant for ID delivery of vaccines that supports a bal

115 gained traction in recent years as potential adjuvants for the induction of adaptive immune responses

116 A Yersinia pestis mutant synthesizing an adjuvant form of lipid A (monophosphoryl lipid A, MPLA)

117 of varying the infection route, the site of adjuvant formulation administration, and standardised th

118 At weaning, offspring were subjected to an adjuvant-free experimental asthma protocol using ovalbum

119 The adjuvant-free vaccine candidates were orally administere

120 ticals, e.g. liquid-formulated vaccines with adjuvants, frequently have poor thermal stability; heati

121 Uptake of antigen and adjuvant from implanted vaccine films by antigen-present

122 The MF59-adjuvanted glycoprotein B (gB) protein subunit vaccine (

123 Group 2 received Ad26.Mos.HIV plus adjuvanted gp140 at weeks 0, 12, and 24.

124 os.HIV alone at week 0 and Ad26.Mos.HIV plus adjuvanted gp140 at weeks 8 and 24.

125 PFS was significantly improved in the adjuvant group (15-year PFS, 29% v 36%, hazard ratio [HR

126 eceiving adjuvant ADT were combined into the adjuvant group.

127 Adjuvant HAI after resection of CRLM is independently as

128 Adjuvant HAI chemotherapy improves overall survival afte

129 Fifty-four percent received adjuvant HAI.

130 The semisynthetic saponin adjuvants have shown significantly different immunostimu

131 mice were immunized twice with a mixture of adjuvanted HBV S and core antigen, followed by a modifie

132 Inhibition of tumor growth in vivo with adjuvant IGFBP-3-Fc with erlotinib versus erlotinib afte

133 l injections of gliadin in complete Freund's adjuvant (immunization) or of soluble gliadin or ovalbum

134 Ideally, the adjuvant in addition stimulates the innate immune system

135 Alum remains the most widely used adjuvant in AIT, but its way of action is not completely

136 critical-size defects and may be a promising adjuvant in regenerative procedures.

137 C) together with an envelope protein (gp120) adjuvanted in alum.

138 n Paper, we summarize current unmet needs of adjuvants in AIT citing current evidence.

139 mpared the efficacy and safety of mechanical adjuvants in mucosal-sparing, mechanical endoscopic dacr

140 proach for codelivering peptide antigens and adjuvants in nanoparticles for inducing anticancer T-cel

141 The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased

142 The combination adjuvant induced robust activation of both NF-kappaB and

143 The qNIV formulation with 75 ug Matrix-M adjuvant induced substantially higher post-vaccination g

144 les were assessed and compared in vivo in an adjuvant-induced arthritis (AA) rat model in order to id

145 Together, these data suggest that adjuvant-induced stimulation of T(h)1-T(fh) cells is an

146 Taken together, these findings show that an adjuvanted influenza vaccine can substantially increase

147 ycles before surgical resection, followed by adjuvant intravenous nivolumab monotherapy for 1 year (2

148 The currently approved adjuvant ipilimumab dose (ipi10) was more toxic and not

149 Here, a new ionic-liquid-based adjuvant is explored, synthesized using two metabolites

150 Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and pers

151 The intended mode of action of adjuvants is to simultaneously enhance the immunogenicit

152 ffects up to 5 years for patients prescribed adjuvant local radiotherapy after primary surgery for ea

153 ctor immunity and a pro-inflammatory vaccine adjuvant may influence RhCMV/SIV vaccine immunogenicity

154 rther studies of the mechanisms of action of adjuvants may advise shorter treatment periods than the

155 moral antibody functions induced by distinct adjuvants may provide a path to designing next-generatio

156 ion adjuvants, respectively, suggesting that adjuvants may weaken or disrupt intermolecular attractio

157 Here, we propose that aluminium-based adjuvants might hold the key to this.

158 AGS-v vaccine alone, 200 nmol of AGS-v with adjuvant (Montanide ISA 51), or sterile water as placebo

159 P (cdAMP) and the plant-derived nanoparticle adjuvant Nano-11 significantly enhanced the immune respo

160 In the adjuvant/neoadjuvant setting, data do not support the ro

161 cterized in part the mechanisms of action of adjuvants on pre-existing immune responses.

162 ontrols received empty Ad5hr vector and alum adjuvant only.

163 her denosumab combined with standard-of-care adjuvant or neoadjuvant systemic therapy and locoregiona

164 ted (2 doses) FLU-v (A-FLU-v or NA-FLU-v) or adjuvanted or nonadjuvanted placebo (A-placebo or NA-pla

165 eptide vaccination in the presence of proper adjuvants or in vitro expansion of the low numbers of se

166 odomain protein (lacking AD-3) with squalene adjuvant, or lipid nanoparticle (LNP)-encapsulated nucle

167 Our findings favor use of an adjuvant over a neoadjuvant approach, without any increa

168 enza vaccines, in stockpiled, emulsion-based adjuvanted pandemic influenza vaccines, and with demonst

169 Improved lead compounds from the adjuvant pipeline are under development and are explored

170 t T cell-independent modality that naturally adjuvants plasma cell differentiation and antibody respo

171 Our findings characterize a novel adjuvant platform and offer an alternative approach to g

172 Thus, it can serve as a promising safe adjuvant platform that can help to protect against pande

173 Adjuvant platinum-based chemotherapy should be considere

174 In poorly radioimmunogenic tumors, the adjuvant polyinosinic-polycytidylic acid overcomes this

175 ponses and efficacy of an aluminum hydroxide adjuvanted purified inactivated Zika vaccine (PIZV) agai

176 the small molecule adjuvant R848 and the RNA adjuvant PUUC, targeting endosomal TLR7s and cytoplasmic

177 Matrix-M-adjuvanted qNIV induced superior wt-HAI antibody respons

178 ys, and study 2, performed with an egg-grown adjuvanted quadrivalent influenza vaccine (aQIVe) using

179 Here, we show that the small molecule adjuvant R848 and the RNA adjuvant PUUC, targeting endos

180 f recurrence included tumor size, grade, and adjuvant radiation.

181 imed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1

182 astoma (GBM) includes surgical resection and adjuvant radiotherapy (RT) and chemotherapy.

183 e that event-free survival was improved with adjuvant radiotherapy compared with early salvage radiot

184 tinence was worse at 1 year for those in the adjuvant radiotherapy group (mean score 4.8 vs 4.0; p=0.

185 ssion-free survival was 85% for those in the adjuvant radiotherapy group and 88% for those in the sal

186 649 (93%) of 697 participants in the adjuvant radiotherapy group reported radiotherapy within

187 therapy at 5 years was 93% for those in the adjuvant radiotherapy group versus 92% for those in the

188 eligible if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy,

189 ould have sufficient power to assess whether adjuvant radiotherapy was superior to early salvage radi

190 0%) to salvage radiotherapy and 697 (50%) to adjuvant radiotherapy.

191 diotherapy (control) to 95% at 10 years with adjuvant radiotherapy.

192 The adjuvanted recombinant glycoprotein E herpes zoster (HZ)

193 e evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous

194 mmunogenicity of a novel, saponin (Matrix-M)-adjuvanted, recombinant hemagglutinin (HA) quadrivalent

195 The two-dose 5-mug adjuvanted regimen induced geometric mean anti-spike IgG

196 s in the absence and presence of formulation adjuvants, respectively, suggesting that adjuvants may w

197 mvPC's immunogenicity, we added a synthetic adjuvant (RS09) to the mvPC design.

198 mong 12 777 214 beneficiaries, the egg-based adjuvanted (RVE, 7.7%; 95% confidence interval [CI], 3.9

199 accharide (as in 5d (beta)) could retain the adjuvant's activity in enhancing IgG1 and IgG2a producti

200 ccharide domain together orchestrate saponin adjuvant's potentiation of immune responses.

201 class of chemotherapy in the neoadjuvant or adjuvant setting (yes or no).

202 In vivo blockade of SHP2 in the adjuvant setting decreased pulmonary metastasis and exte

203 egalovirus-specific (CMV-specific) ACT in an adjuvant setting for patients with primary GBM, with an

204 oadjuvant or concurrent versus concurrent or adjuvant short-term ADT.

205 Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP immunog

206 Since each class of the laser adjuvant shows a distinct mechanism of action, a proper

207 ons, these characteristics render the "laser adjuvant" significant advantages for clinical use and op

208 ells were detected with the IL-4R antagonist adjuvanted strategy compared to the unadjuvanted control

209 Presented results indicate that the QAC adjuvant system can offer a safer alternative to the use

210 In this study, we evaluate a novel adjuvant system developed from Quil-A and chitosan (QAC)

211 The QAC adjuvant system forms nanocarriers (<100 nm) that effici

212 geted therapy should be offered 14 cycles of adjuvant T-DM1, unless there is disease recurrence or un

213 o promptly identify patients who do not take adjuvant tamoxifen as prescribed and are at risk for poo

214 uate the rate of biochemical nonadherence to adjuvant tamoxifen using serum assessment and to examine

215 therapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer.

216 being tested in clinical trials, may render adjuvant targeted therapy less effective due to prolifer

217 tive factors and mechanisms of resistance to adjuvant targeted therapy.

218 response assessment in glioma patients after adjuvant temozolomide chemotherapy (TMZ).

219 e trial of radiotherapy plus concomitant and adjuvant temozolomide published in 2005.

220 identifies ospemifene as a novel antifungal adjuvant that augments the antifungal activity of itraco

221 used vaccines, and the inclusion of a strong adjuvant that has been minimally studied in clinical set

222 demonstrated an intranasal (IN) nanoemulsion adjuvant that redirects allergen-specific Th2 responses

223 gB protein with an MF59-like squalene-based adjuvant, the gB ectodomain protein (lacking AD-3) with

224 acted great interest for both diagnostic and adjuvant therapeutic interventions.

225 radiotherapy is not clearly established, but adjuvant therapies can offer better outcomes in patients

226 es and evaluating the impact of contemporary adjuvant therapies on the risk of CNS metastasis develop

227 prove the visualization of tumor margins and adjuvant therapies to ablate remaining tumor tissues are

228 INK1 upregulation, and offers a strategy for adjuvant therapies.

229 could be initiated before administration of adjuvant therapies.

230 tients met study criteria: 313 (78%) without adjuvant therapy and 90 who received adjuvant chemothera

231 Patients received adjuvant therapy at physician's discretion.

232 without detriment to help select appropriate adjuvant therapy based on tumour Ki67.

233 ess of self- retained cryopreserved AM as an adjuvant therapy for infectious corneal ulcers.

234 Sorafenib should not be used as adjuvant therapy for RCC.

235 -induced ALI in mice and may be useful as an adjuvant therapy in future pre-clinical studies.

236 rioperative complications; (3) Completion of adjuvant therapy in the perioperative format is difficul

237 In-office sutureless AM may be an effective adjuvant therapy in treating sight-threatening infectiou

238 high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically mea

239 ents may require aggressive follow-up and/or adjuvant therapy to mitigate their poor outcomes.

240 am pathway, would provide a novel target for adjuvant therapy when treating pelvic cancers with radia

241 BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulte

242 Adjuvant therapy with ipi3 benefits survival versus HDI;

243 uscle invasive tumors that do not respond to adjuvant therapy with the standard-of-care immunotherapy

244 174 postmenopausal patients (2.8 years after adjuvant therapy) with impaired peak oxygen consumption

245 platin (mFOLFIRINOX) is the standard-of-care adjuvant therapy, although data from several randomized

246 the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant i

247 potential use of combination biomarkers for adjuvant therapy.

248 significant survival benefit compared to no adjuvant therapy.

249 status, PR status, and HER2 status, and (neo)adjuvant therapy.

250 ry systems have been investigated as vaccine adjuvants, though few direct comparisons exist.

251 Results: After 2 cycles of adjuvant TMZ chemotherapy, a treatment-induced reduction

252 to be helpful for identifying responders to adjuvant TMZ early after treatment initiation.

253 (bNAbs) represent a potential alternative or adjuvant to ART.

254 diseases, exogenous LTB(4) can be used as an adjuvant to boost inflammasome-dependent host defense.

255 These natural anti-Gal Abs can be used as an adjuvant to enhance processing of vaccine epitopes to AP

256 al studies of a fasting-mimicking diet as an adjuvant to oestrogen therapy in hormone-receptor-positi

257 that it is technically possible for a single adjuvant to reverse innate antibiotic resistance in all

258 ory response, corticosteroids are used as an adjuvant to standard antimicrobial therapy.

259 n significant attention as new drugs or drug adjuvants to combat multidrug-resistant bacteria.

260 ce anti-inflammatory drugs are beneficial as adjuvants to conventional and immune-based therapies, we

261 ary phytochemicals have been investigated as adjuvants to conventional anti-tumor therapeutics, offer

262 Including these adjuvants to conventional oral hygiene have shown to imp

263 ress signaling and have potential for use as adjuvants to enhance the activity of ABCB1 inhibitors.

264 ctive studies investigating the influence of adjuvants to oral hygiene procedures on the recurrence o

265 ligands in indoor dust act as environmental adjuvants to promote sensitization to inhaled peanut in

266 es that these drugs could represent relevant adjuvants to the anti-IL-1 drugs in patients with CAPS a

267 and HER2-targeted therapy were allocated to adjuvant trastuzumab emtansine (T-DM1; n = 743) or to tr

268 nt therapy, and surgery have been completed; adjuvant treatment and follow-up are ongoing.

269 entially could be used to guide selection of adjuvant treatment by avoiding therapy in very low risk

270 ed poor prognosticator and an indication for adjuvant treatment escalation in patients with head and

271 ogen-dependent signaling is a cornerstone of adjuvant treatment for breast cancer, 25% of patients ex

272 They suggest using (223)RaCl(2) as an adjuvant treatment for select patients at early stages o

273 festyle interventions for the prevention and adjuvant treatment of hypertension.

274 herapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially

275 Adjuvant treatment was given as per UK standard local pr

276 lopment of de-escalation trials for systemic adjuvant treatment, including noninferiority trial desig

277 37.3% and 23.4% v 46.6% for neoadjuvant and adjuvant treatment, respectively).

278 adjuvant chemotherapy and 325 (64.5%) had no adjuvant treatment.

279 Fourteen of 16 patients received adjuvant treatments.

280 This retrospective analysis of a large adjuvant trial highlights a differential response to doc

281 from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB-C or

282 Phase III adjuvant trials have reported significant benefits in bo

283 We reviewed several adjuvant trials of different cancer types and developed

284 bstitute for OS to accelerate phase III (neo)adjuvant trials of prostate cancer therapies for primary

285 sed high-dose trivalent (HD-IIV3), egg-based adjuvanted trivalent (aIIV3), egg-based standard dose (S

286 ting the contributions of antigen amount and adjuvant use to VE.

287 ssigned 49 healthy adult participants to the adjuvanted vaccine (n=17), vaccine alone (n=16), or plac

288 toms and were significantly increased in the adjuvanted vaccine group compared with both other treatm

289 ral blood mononuclear cells at day 42 in the adjuvanted vaccine group compared with in the placebo gr

290 groups (nine [53%] of 17 participants in the adjuvanted vaccine group, two [13%] of 16 in the vaccine

291 By day 42, participants who were given the adjuvanted vaccine had a significant increase in vaccine

292 assigned (1:1) to receive an HPV 16/18 AS04-adjuvanted vaccine or control hepatitis A vaccine.

293 Self-adjuvanting vaccines, wherein an antigenic peptide is co

294 ificant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address eme

295 ses in humans after vaccination with an AS03-adjuvanted versus nonadjuvanted H5N1 avian influenza vir

296 production) and biodistribution (antigen and adjuvant) were evaluated in vivo.

297 Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast canc

298 Finally, when adjuvanted with aluminum hydroxide and administered to B

299 ide (Al(OH)(3) ) is the most frequently used adjuvant, with microcrystalline tyrosine (MCT), monophos

300 Our findings demonstrate that self-adjuvanting Y. pestis OMVs provide a novel plague vaccin